Head-to-head evidence
BEBT-109 vs TY-9591
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BEBT-109
Developed by BeBetter Med
NCT06001671 · Phase 1 · completed
This was a small, single-arm, dose-escalation study with no control group and effectively no blinding of participants or investigators; it was designed to find a tolerable dose, not to test whether the drug worked, and results have not yet been reported.
Next expected readout: June 2027 · NCT06514027 (registry estimate)
TY-9591
Developed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BEBT-109's landscape · TY-9591's landscape